Metastatix, Inc. Completes Series A Financing; H.I.G. Ventures Leads $3.6 Million Round For Atlanta-Based Biopharmaceutical Company
9/7/2006 2:43:43 PM
ATLANTA--(BUSINESS WIRE)--Sept. 7, 2006--Metastatix, Inc., an Atlanta-based biopharmaceutical company developing small-molecule drugs to treat cancer and HIV, announced today it has raised a $3.6 million Series A financing round. The funds will be used for the development of initial clinical candidates and will advance the cancer program to the point of filing an investigational new drug application (IND) with the FDA.
comments powered by